Fundraising FoxVibliome Therapeutics
Bozeman, US · Founded 2017 · Delaware LLC · 1 known investors
Find your way into Vibliome Therapeutics
Sign up to see every warm intro you have to Vibliome Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vibliome Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JL
JAMES LINFIELDNamed on SEC filing
GF
GARY FLYNNNamed on SEC filing
RG
ROBERT GOODWINNamed on SEC filing
BS
BRYAN SENDROWSKINamed on SEC filing
CW
RJ
ROBERT JACKSONNamed on SEC filing
MF
MICHAEL FARRELLNamed on SEC filingHead of Portfolio Company Operations at Deerfield Management Company
JR
JONATHAN RAMOSNamed on SEC filing
Investors · 1
Deerfield Management CompanyreportedNew York
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$8.1M disclosed across 2 rounds · 2018–2019
▶$8MraisedFeb 2019 · 2 investors · OtherRule 506(b)
▶$8MraisedFeb 2019 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT GOODWINExecutive Officer, Director, Promoter
- BRYAN SENDROWSKIExecutive Officer
- GARY FLYNNExecutive Officer, Promoter
- CAMERON WHEELERDirector
- ROBERT JACKSONDirector
- MICHAEL FARRELLExecutive Officer
- JONATHAN RAMOSExecutive Officer
- Offering amount
- $16M
- Amount sold
- $8M
- First sale
- Feb 2019
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
▶$113KraisedApr 2018 · 3 investors · OtherRule 506(b)
▶$113KraisedApr 2018 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- JAMES LINFIELDExecutive Officer
- GARY FLYNNExecutive Officer, Director, Promoter
- ROBERT GOODWINExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $113K
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Vibliome Therapeutics's investors?
- Vibliome Therapeutics's investors include Deerfield Management Company.
- How much funding has Vibliome Therapeutics raised?
- Vibliome Therapeutics has disclosed $8.1M raised across 2 rounds.
- Where is Vibliome Therapeutics headquartered?
- Vibliome Therapeutics is headquartered in Bozeman, US.